Search Results - S. Fatenejad

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

    Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor in... by E. Feist, S. Fatenejad, S. Grishin, E. Korneva, M.E. Luggen, E. Nasonov, M. Samsonov, J.S. Smolen, R.M. Fleischmann

    Published 2023-04-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

    Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment by Eugen Feist, Roy M. Fleischmann, Saeed Fatenejad, Daria Bukhanova, Sergey Grishin, Sofia Kuzkina, Michael Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S. Smolen

    Published 2024-12-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: